Chapter 108. Vaccination of Allogeneic and Autologous Hematopoietic Cell Recipients

  1. Frederick R. Appelbaum MD Member Director Professor Head2,3,
  2. Stephen J. Forman MD Director Staff Physician4,5,
  3. Robert S. Negrin MD Professor of Medicine Chief6 and
  4. Karl G. Blume MD, FACP Emeritus Professor of Medicine6,7
  1. Trudy N. Small MD

Published Online: 5 MAR 2009

DOI: 10.1002/9781444303537.ch108

Thomas' Hematopoietic Cell Transplantation: Stem Cell Transplantation, Fourth Edition

Thomas' Hematopoietic Cell Transplantation: Stem Cell Transplantation, Fourth Edition

How to Cite

Small, T. N. (2009) Vaccination of Allogeneic and Autologous Hematopoietic Cell Recipients, in Thomas' Hematopoietic Cell Transplantation: Stem Cell Transplantation, Fourth Edition (eds F. R. Appelbaum, S. J. Forman, R. S. Negrin and K. G. Blume), Wiley-Blackwell, Oxford, UK. doi: 10.1002/9781444303537.ch108

Editor Information

  1. 2

    Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA

  2. 3

    Division of Medical Oncology, University of Washington School of Medicine, Seattle, Washington, USA

  3. 4

    Department of Hematology and Hematopoietic Cell Transplantation, Duarte, California, USA

  4. 5

    Department of Medical Oncology and Therapeutics Research, City of Hope Comprehensive Cancer Center, Duarte, California, USA

  5. 6

    Division of Blood and Marrow Transplantation, Stanford University, Stanford, California, USA

  6. 7

    Division of Bone Marrow Transplantation, Department of Medicine, Stanford University, School of Medicine, Stanford, California, USA

Author Information

  1. Associate Attending, Department of Pediatrics Bone Marrow Transplantation Service, Memorial Sloan-Kettering Cancer Center, New York, New York, USA

Publication History

  1. Published Online: 5 MAR 2009
  2. Published Print: 27 FEB 2009

ISBN Information

Print ISBN: 9781405153485

Online ISBN: 9781444303537

SEARCH

Keywords:

  • vaccination of allogeneic and autologous hematopoietic cell recipients;
  • immunogenicity of vaccines post HCT;
  • recently approved vaccines;
  • loss of protective titers following HCT;
  • Centers for Disease Control (CDC);
  • European Group for Blood and Marrow Transplantation (EBMT);
  • CDC and EBMT post-vaccine guidelines

Summary

This chapter contains sections titled:

  • Introduction

  • Loss of protective titers following HCT

  • Immunogenicity of vaccines post HCT

  • Recently approved vaccines

  • Conclusion

  • References